PubMed Health⌕ Search

PubMed · 8020045

[Is sympathetic hyperactivity a coronary risk factor?].

Abstract

Clinical and experimental data have suggested a role of enhanced sympathetic nervous activity in the pathogenesis and evolution of coronary heart disease. A significant relationship was observed between the circadian pattern of plasma catecholamine levels and the onset of coronary events, which occur most frequently in the early morning, concomitance with sympathetic activation. An enhanced sympathetic tone is frequently observed in both the acute phase of myocardial infarction and in the postinfarction period, potentiating myocardial damage and increasing the risk of arrhythmias. An indirect demonstration of the importance of sympathetic activation arises from the results of several trials on the effects of beta-blocker treatment during and after myocardial infarction, showing a significant reduction in total mortality, sudden deaths and reinfarction. There is accumulating evidence that repeated activation of sympathetic nervous system may contribute to atheroma development and progression. Enhanced sympathetic activity seems to be involved in the pathogenesis and maintenance of essential hypertension as well as in its natural history, contributing to the development of left ventricular hypertrophy and vascular hypertrophy. The problems in measuring and defining the various levels of autonomic activity in human beings and the complexity of the relationship between nervous and non nervous factors in cardiovascular diseases make difficult to establish whether sympathetic hyperactivity represents an independent cardiovascular risk factor.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

R Fogari, A Zoppi. 1993. [Is sympathetic hyperactivity a coronary risk factor?].. https://pubmed.ncbi.nlm.nih.gov/8020045/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗